PG

Priti Gehlot

Active Director Director DIN 10406030
DIN 10406030 First appointment Nov 2023
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Nov 2023
Shareholding value β€’β€’β€’β€’ Premium profile

About Priti Gehlot

Data last updated:

Priti Gehlot is a Director at Argentos Pharma Private Limited (since 2023).

DIN 10406030
Primary Designation Director
First Appointment 28 Nov 2023
Oldest Company Age 2 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Argentos Pharma Private Limited U32500DL2023PTC423133
Director28 Nov 20232023Active

Board colleagues of Priti Gehlot

NameDINCompanyDesignation
Mahesh Kumar Garg07775640Argentos Pharma Private LimitedAdditional Director
Sunita Yadav03533100Argentos Pharma Private LimitedAdditional Director
Tapendra Vishnoi08760687Argentos Pharma Private LimitedDirector

Directorship timeline

Open interactive timeline →
Argentos Pharma Private Limited
Premium access

Shareholding and investment profile for Priti Gehlot

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Priti Gehlot

Priti Gehlot currently holds 1 directorship: Argentos Pharma Private Limited (Director, since 28 Nov 2023).

Priti Gehlot was first appointed on 28 Nov 2023 as Director at Argentos Pharma Private Limited.

The current boards of Priti Gehlot's companies include Mahesh Kumar Garg (Argentos Pharma Private Limited), Sunita Yadav (Argentos Pharma Private Limited), Tapendra Vishnoi (Argentos Pharma Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available